Impact of GLP-1 Medications on Food Consumption and Industry Trends

The rise of GLP-1 medications, such as Ozempic and Mounjaro, has significantly altered eating habits among millions of Americans, leading to a decline in overall food consumption while simultaneously increasing the demand for higher-priced, protein-rich foods. This shift is prompting changes across the food and beverage industry, affecting both grocery stores and restaurants.

Research indicates that approximately half of GLP-1 users report consuming fewer calories, with a notable 70% of these individuals snacking less. This trend has particularly impacted categories like savory snacks and sugary beverages, which have seen declines of up to 50% among users. Instead, consumers are gravitating towards healthier options, such as protein-rich foods and vegetables, which tend to be more expensive. For instance, a meat stick from Chomps costs $2–$3, while traditional snacks like potato chips are priced around $1.

Food companies are responding to these changing consumer preferences by innovating their product offerings. For example, Nestlé launched the Vital Pursuit line, targeting GLP-1 users with frozen meals that emphasize protein and fiber. Similarly, Conagra has expanded its high-protein options under the Healthy Choice brand. Executives from major food corporations, including PepsiCo and Domino's Pizza, have expressed optimism about the opportunities presented by this trend, focusing on healthier menu options to attract health-conscious consumers.

The shift in consumer behavior is reshaping grocery store layouts, with retailers allocating more shelf space to protein snacks and nutrition drinks while reducing space for traditional impulse snacks. This change is not only affecting GLP-1 users but is also leading to higher grocery prices for all consumers. Retail strategist Carol Spieckerman noted that the demand for health-oriented products is driving up prices, as companies introduce higher-margin items to offset declining sales of cheaper snacks.

While many in the industry view the trend as an opportunity, there are concerns regarding the rising costs associated with healthier food options. Critics argue that as grocery prices increase, the affordability of nutritious foods may become a barrier for lower-income consumers. This shift could exacerbate existing inequalities in food access, making it more challenging for some populations to maintain healthy diets.

As the adoption of GLP-1 medications continues to grow, the food industry is likely to see further changes in consumer preferences and product offerings. Companies will need to remain agile, adapting their strategies to meet the evolving demands of health-conscious consumers. The long-term implications of this trend could reshape the landscape of both grocery and restaurant sectors, emphasizing the importance of protein-rich and nutrient-dense foods in the marketplace.

• "GLP-1 usage has absolutely been a hot conversation among retailers. It upended purchasing models and category assumptions that had stood the test of time." — Carol Spieckerman, Retail Strategist

• "More customers want control over their choices, and they want these choices to be health-aligned." — Teneshia Murray, Restaurant Owner

• "The rise of GLP-1 medications is reshaping how Americans shop and dine." — Whitney Stuart, Media Dietitian and Diabetes Educator

• "I think there are more opportunities than threats, but there are both." — Ramon Laguarta, CEO of PepsiCo

CNBC

• "This is a trend that's not going away." — Dana Baggett, Executive Director of Restaurant Client Strategy at RRD

CNBC